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Currently, platinum-based combination chemotherapy is the standard first-line 
chemotherapy for non-small-cell lung cancer (NSCLC). Historically, platinum-based 
chemotherapy has been recommended for up to six cycles even for responders, and 
second-line chemotherapy has been considered when disease progression is confirmed. 
In spite of extensive investigations into maintenance chemotherapy, no positive data 
have been obtained; however, the results of recent clinical trials suggest both the safety 
and efficacy of maintenance chemotherapy in patients with NSCLC, although it is still 
controversial. In this review, we summarize the major clinical trials of maintenance 
chemotherapy in patients with NSCLC, and discuss its clinical validity and present 











Lung cancer is the leading cause of cancer-related death in many industrialized 
countries. Platinum-based combination chemotherapy has been shown to improve the 
survival and quality of life of patients with advanced non-small-cell lung cancer 
(NSCLC); however, chemotherapy for advanced NSCLC has been of limited benefit, 
and seems to have reached a plateau.
1, 2
 Historically, platinum-based chemotherapy has 
been recommended up to four to six cycles, and a ‘watch and wait’ strategy until disease 
progression has been considered a reasonable therapeutic strategy. 
 Maintenance chemotherapy is a promising treatment strategy to improve 
survival and has been extensively investigated; however, no positive results have been 
obtained. Recently, effective second-line chemotherapy, such as docetaxel, pemetrexed, 
gefitinib, and erlotinib, has been developed.
3-7
 Nevertheless, it is said that only about 
50% of NSCLC patients in clinical trials go on to receive second-line chemotherapy.
8
 
This fact prompted the exploration of a maintenance strategy, and some positive results 
have been reported recently. 
 Maintenance chemotherapy is defined as the prolongation of treatment duration 
with the administration of additional drugs at the end of a defined number of initial 
chemotherapy cycles after achieving tumor control, and has been extensively 
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investigated in patients with NSCLC. It consists of drugs included in the induction 
regimen or other non-cross-resistant agents. Although the terminology is still confusing, 
according to the recent literature, when drugs included in the induction regimen are used 
it is called ‘continuation maintenance’, and when other non-cross-resistant agents are 
used it is called ‘switch maintenance’ or ‘early second-line’.9, 10 
 In this review, we summarized recent major clinical trials of maintenance 
chemotherapy in patients with NSCLC. 
 
Duration of first-line chemotherapy 
Platinum-based combination chemotherapy is the standard first-line regimen for 
NSCLC; however, the duration of the platinum regimen has been a matter of debate. 
Current major guidelines recommend that platinum-based chemotherapy should be 
administered for no more than six cycles.
11-13
 Randomized trials on which these 
guidelines are based are summarized in Table 1. 
 Smith et al. conducted a phase III trial comparing three and six cycles of 
mitomycin, vinblastine, and cisplatin (MVP) in 308 patients. Seventy-three percent of 
patients randomized to six cycles completed three cycles and 31 % six cycles, while 
72% of patients randomized to three cycles completed treatment. Median time to 
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disease progression (TTP) was 5 months for both arms, and median survival time 
(MST) was 6 months in the 3-cycle arm and 7 months in the 6-cycle arm, respectively 
(p=0.2). Quality-of-life (QOL) parameters were almost identical between the two arms; 




 Socinski et al. performed a phase III trial in which 230 patients were 
randomized to either four cycles of carboplatin and paclitaxel (CP) or CP until disease 
progression. The median number of treatment cycles was four in both arms. There were 
no significant differences in MST between the two arms (p=0.63). TTP was not reported 
in the study. There were no differences in toxicities, except for neuropathy; however, the 
QOL of both treatment arms was not significantly different.
15
  
 In the trial conducted by von Plessen et al., three and six cycles of carboplatin 
and vinorelbine were compared in 297 patients. Survival data and QOL were not 
significantly different between the two arms. The authors concluded that more than 




 In the recent trial conducted by Park et al., patients with stages IIIB or IV 
NSCLC who had not progressed after two cycles of cisplatin-based chemotherapy were 
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randomly assigned to receive either four (6-cycle arm) or two (4-cycle arm) more cycles 
of chemotherapy. There were no significant differences in MST (14.9 months vs. 15.9 
months, p=0.461); however, median TTP was significantly longer in the 6-cycle arm 
(6.2 months vs. 4.6 months, p=0.001). Patients in the 4-cycle arm showed significant 
improvement in role-functioning from the completion of four cycles to 3 months later, 
and also experienced less nausea/vomiting, sore mouth, and dyspnea than the 6-cycle 
arm. In addition, patients in the 6-cycle arm significantly less frequently received 
second-line chemotherapy than the 4-cycle arm (62.7% vs. 74.4%, p=0.026), which may 
explain why the difference in TTP did not translate into overall survival (OS). The 
authors speculated that toxicities or a declining performance status (PS) might have led 
to the lower frequency of the use of second-line chemotherapy in the 6-cycle arm.
17
 
Nevertheless, their results suggested that further investigation of maintenance 
chemotherapy with less toxic agents is warranted. 
 
Cytotoxic agents 
Continuation maintenance (summarized in Table 2) 
Paclitaxel 
Belani et al. conducted a phase III trial in which patients whose disease did not progress 
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after initial chemotherapy with carboplatin and paclitaxel were randomly assigned to 
either weekly paclitaxel (n=65) or observation (n=65). Median TTP and MST were 38 
weeks and 75 weeks in the paclitaxel arm, and 29 weeks and 60 weeks in the 






In the trial conducted by Brodowicz et al., patients achieving an objective response or 
disease stabilization following initial chemotherapy with cisplatin and gemcitabine were 
randomized to the maintenance gemcitabine arm (n=138) or best supportive care (BSC) 
arm (n=68). Median TTP throughout the study period was 6.6 and 5.0 months for the 
gemcitabine and BSC arms, respectively (p＜0.001), while values in the maintenance 
period were 3.6 and 2.0 months (p＜0.001). MST throughout the study was 13.0 months 
for the gemcitabine arm and 11.0 months for the BSC arm (p=0.195). The toxicity 
profile was mild, with neutropenia being the most common grade 3/4 toxicity.
19
 
 In the 2010 American Society of Clinical Oncology (ASCO) annual meeting, 
Belani et al. presented the results of a phase III trial evaluating the efficacy of 
gemcitabine as maintenance therapy. In the trial, patients with wet stage IIIB/IV 
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NSCLC were initially treated with carboplatin and gemcitabine every 3 weeks for 4 
cycles. Subsequently, patients with CR/PR or SD were randomized 1:1 to receive 
maintenance gemcitabine every 3 weeks with BSC or BSC alone until disease 
progression. Following 4 cycles of carboplatin and gemcitabine, 255 non-progressive 
patients were randomized to receive gemcitabine + BSC (n=128) or BSC alone (n=127). 
The median progression-free survival (PFS) was 3.9 months for gemcitabine and 3.8 
months for BSC arms. MST was 8.0 months for gemcitabine and 9.3 months for BSC. 
The differences in survival between the two arms were not statistically significant 
(HR=0.97 [95% CI: 0.72, 1.30], p=0.84). Maintenance therapy was well tolerated 
despite a higher incidence of grade 3/4 toxicity (anemia 9.4% vs. 2.4%; neutropenia 
13.3% vs. 1.6%; thrombocytopenia 9.4% vs. 1.4%; and fatigue 3.9% vs. 1.6%). The 
author concluded that it was a negative study, mentioning that nearly two thirds of 




 In the same meeting, Perol et al. presented the results of an interesting phase III 
trial, in which stage IIIB/IV patients with PS of 0-1 whose tumors did not progress 
following four cycles of cisplatin-gemcitabine were randomized to observation (n=155), 
or to receive either gemcitabine (n=154) or erlotinib (n=155) as maintenance therapy 
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until disease progression. Second-line chemotherapy was pre-defined as pemetrexed. 
Median PFS was 1.9 months in the observation arm, 3.8 months in the gemcitabine arm, 
and 2.9 months in the erlotinib arm, respectively. The difference between the 
observation arm and gemcitabine arm (p＜0.0001) or erlotinib arm (p=0.002) was 
significant. OS was not significantly different; however, the OS data were immature and 
there was a tendency in favor of maintenance chemotherapy. In addition, both drugs had 
manageable toxicities in the maintenance setting.
21
 Final results are awaited. 
 
Switch maintenance (summarized in Table 3) 
Vinorelbine 
In a phase III trial conducted by Westeel et al., 573 patients with stage IIIB and IV 
NSCLC were initially treated with mitomycin, ifosfamide, and cisplatin (MIC). Those 
with stage IIIB disease received two cycles of MIC followed by thoracic radiation, and 
those with wet IIIB and IV disease received four cycles of MIC. Of 227 patients who 
responded to initial treatment, 181 were randomized to either maintenance chemotherapy 
with weekly vinorelbine for 6 months (n=91) or observation (n=90).  One- and 2-year 
survival rates were 42.2% and 20.1% in the vinorelbine arm and 50.6% and 20.2% in the 
observation arm, respectively (p=0.48). The hazard ratio of survival after adjustment for 
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stage in the vinorelbine arm relative to the observation arm was 1.08 (95% CI: 0.79, 1.47, 
p=0.65). There was also no difference between the two arms in PFS (p=0.32). The main 
toxicity was hematologic, and it was more frequently observed in patients who had 






Fidias et al. conducted a phase III trial in which patients with wet IIIB or IV NSCLC were 
enrolled. In the trial, patients were initially treated with four cycles of chemotherapy with 
carboplatin and gemcitabine, and those who did not have progression were randomly 
assigned to either immediate or delayed docetaxel. In the immediate group, docetaxel 
was initiated from day 21 up to day 35 after the start of cycle 4 of initial chemotherapy. 
In the delayed group, in contrast, docetaxel was given only at the time of documented 
progression. After four cycles of initial chemotherapy, 309 of 566 patients were deemed 
non-PD and were randomized to either immediate or delayed docetaxel. Of the patients 
randomized to immediate docetaxel, 94.8% of patients received at least one treatment 
cycle, whereas only 62.8% of patients randomized to the delayed arm ever received 
docetaxel. The most common reasons for not receiving docetaxel in the delayed arm 
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were disease progression, patient or investigator decision, and death. Median PFS was 
significantly better in the immediate arm than the delayed arm (5.7 vs 2.7 months, 
p=0.0001). OS was also better in the immediate arm; however, the difference was not 
significant (12.3 vs 9.7 months, p=0.0853). When the survival of patients who actually 
received docetaxel in the delayed arm was compared with that of treated patients in the 
immediate arm, OS was identical (12.5 months for both groups). There were no 





More recently, pemetrexed has been examined as maintenance chemotherapy. In the 
trial conducted by Ciuleanu et al., patients who had not progressed on four cycles of 
platinum-based chemotherapy were randomly assigned in a 2:1 ratio to either 
maintenance pemetrexed (n=441) or placebo (n=222). Median PFS was 4.3 months in 
the pemetrexed arm and 2.6 months in the placebo arm (p＜0.0001). OS was also 
significantly favored in the pemetrexed arm (13.4 vs 10.6 months, p=0.012). Subgroup 
analysis revealed that the survival benefit of maintenance pemetrexed was seen in 
patients with non-squamous histology but not in patients with squamous histology. 
Median PFS was 4.4 months in the pemetrexed arm and 1.8 months in the placebo arm, 
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for non-squamous histology (p＜0.0001), whereas 2.4 months in the pemetrexed arm 
and 2.5 months in the placebo arm for squamous histology (p=0.896). MST was 15.5 
months in the pemetrexed arm and 10.3 months in the placebo arm for non-squamous 
histology (p＜0.0001), whereas 9.9 months in the pemetrexed arm and 10.8 months in 
the placebo arm for squamous histology (p=0.678). Pemetrexed toxicities were 
generally mild, and no treatment-related deaths were observed. For post-study treatment, 
only 18% of patients received pemetrexed in the placebo arm.
24
 There is a criticism that 
this study did not show that the timing of subsequent therapy is crucial, but only showed 





Molecular-targeted agents  
Continuation maintenance (summarized in Table 4) 
Bevacizumab 
There have been two large randomized phase III trial of bevacizumab for NSCLC, one 
of which was conducted by the Eastern Cooperative Oncology Group (ECOG), E4599. 
In this trial, patients with stage IIIB/IV, non-squamous histology were randomly 
assigned to either chemotherapy with carboplatin and paclitaxel alone (n=444) or 
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carboplatin and paclitaxel plus bevacizumab 15mg/kg (n=434). Chemotherapy was 
repeated for up to six cycles unless there was evidence of disease progression. Patients 
in the bevacizumab arm were administered bevacizumab concurrently with 
chemotherapy and continued to receive bevacizumab monotherapy every 3 weeks until 
disease progression or intolerable toxicities. Both PFS and OS were significantly better 
in the bevacizumab arm (6.2 vs 4.5 months, HR 0.66 [95% CI 0.57, 0.77], p<0.001 for 
PFS; 12.3 vs 10.3 months, HR 0.79 [95% CI 0.67, 0.92], p=0.003 for OS).
26
 
 In the other trial (AVAstin In Lung cancer: AVAiL) conducted in Europe, 
patients with non-squamous NSCLC were randomly assigned to either chemotherapy 
with cisplatin and gemcitabine alone (n=347), cisplatin and gemcitabine plus 
bevacizumab 7.5mg/kg (n=345), or cisplatin and gemcitabine plus bevacizumab 
15mg/kg (n=351). PFS, the primary endpoint, was significantly better in the 
bevacizumab arms than the chemotherapy-alone arm (6.7 vs 6.1 months, p=0.003 for 
low-dose bevacizumab and 6.5 vs 6.1 months, p=0.03 for high-dose bevacizumab); 
however, the differences were not translated into OS.
27, 28
 
 In both trials, bevacizumab was administered from the beginning, concurrently 
with chemotherapy. There are no conclusive data on the necessity of maintenance 
bevacizumab; however, a recent randomized trial of bevacizumab for gynecologic 
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cancer suggested the effectiveness of a maintenance phase.
29
 Further investigations are 
needed also in the field of NSCLC. 
 
Cetuximab 
Pirker et al. conducted a phase III trial (First-Lin ErbituX in lung cancer: FLEX) in 
which patients with EGFR-expressing wet IIIB or IV NSCLC were randomized either to 
chemotherapy with cisplatin and vinorelbine alone (n=568) or cisplatin and vinorelbine 
plus cetuximab (n=557). In the cetuximab arm, cetuximab was administered 
concurrently with chemotherapy and was continued after the end of chemotherapy until 
PD or unacceptable toxicity. Median PFS was 4.8 months in each arm; however, OS 
was significantly better in the cetuximab arm (median 11.3 vs 10.1 months, HR=0.871 
[95% CI: 0.762, 0.996], p=0.044). More patients in the chemotherapy-alone arm started 
second-line chemotherapy without documented disease progression, and analysis of 
time-to-treatment failure as a posthoc sensitivity analysis for PFS showed a significant 
benefit for cetuximab.
30
 In the other study, in which cetuximab was combined with 








Concurrent administration of gefitinib with chemotherapy failed to show survival 
advantages over chemotherapy alone.
32, 33
 The West Japan Thoracic Oncology Group 
(WJTOG) carried out a phase III trial to evaluate whether gefitinib improves survival as 
maintenance therapy after platinum-based chemotherapy. In this study, 
chemotherapy-naïve patients with stage IIIB/IV NSCLC were randomly assigned to 
either platinum-doublet chemotherapy for up to six cycles (arm A, n=301) or 
platinum-doublet chemotherapy for three cycles followed by gefitinib until disease 
progression (arm B, n=302). Median PFS was 4.3 months for arm A and 4.6 months for 
arm B, and there was a statistically significant difference (p＜0.001); however, MST 
was almost identical between the two arms (12.9 months for arm A, 13.7 months for 
arm B; p=0.11). Exploratory subset analysis revealed possible prolongation with 
sequential therapy of gefitinib, especially in patients with adenocarcinoma.
34
 
 The European Organization for Research and Treatment of Cancer (EORTC) 
conducted a phase III trial in which patients with advanced NSCLC not progressing 
after 4 cycles of platinum-based chemotherapy were randomized to receive either 
gefitinib or a matched placebo until progression or unacceptable toxicity. After the 
inclusion of 173 patients, the trial was prematurely closed to entry due to low accrual. 
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As a result, 86 and 87 patients were randomized to either gefitinib or placebo, 
respectively. MST was not statistically different (10.9 months for gefitinib arm and 9.4 
months for placebo arm, HR 0.83 [95% CI 0.60, 1.15], p = 0.2); however, PFS was 






As with gefitinib, concurrent administration of erlotinib with chemotherapy was not 
superior to chemotherapy alone.
36, 37
 Sequential Tarceva in Unresectable NSCLC 
(SATURN) is a randomized, placebo-controlled phase III trial comparing maintenance 
erlotinib with a placebo.  In this trial, 1949 chemo-naïve patients were initially treated 
with four cycles of platinum-based chemotherapy. Those who did not progress on 
treatment were then randomized to receive either erlotinib (n=438) or placebo (n=451). 
Approximately, 45% of patients had adenocarcinoma histology and 40% had squamous 
cell carcinoma histology in each arm. The primary endpoint was PFS, and patients were 
stratified by a number of clinical factors as well as their epidermal growth factor 
receptor (EGFR) protein expression status, assessed by immunohistochemistry, and 
EGFR gene copy number, assessed by fluorescent in situ hybridization. Both PFS and 
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OS were significantly better in the erlotinib arm (12.3 weeks vs 11.1 weeks, HR 0.71 
[95% CI 0.62, 0.82], p<0.0001 for PFS; 12.0 months vs 11.0 months, HR 0.81 [95% CI 
0.70, 0.95], p=0.0088 for OS). Biomarker analysis showed no significant interaction of 
EGFR protein expression or EGFR gene copy number. Patients with EGFR-activating 
mutations in exon 19 or 21 derived significantly greater PFS benefit from maintenance 
erlotinib (HR 0.10, p<0.0001) than those patients with EGFR wild-type tumors (HR 
0.78, p=0.018); however, OS was not significantly different due to extensive cross-over 
to erlotinib at the time of progression.
38
 
 The ATLAS trial was designed to evaluate bevacizumab + erlotinib vs. 
bevacizumab + placebo following bevacizumab + platinum-containing doublet 
chemotherapy in patients with chemo-naïve, stage IIIb/IV NSCLC. In the trial, 743 
stable and responding patients remained on maintenance bevacizumab and were 
randomly assigned to receive oral erlotinib 150 mg daily or placebo. The majority of 
patients included had adenocarcinoma histology (81.3% in erlotinib arm and 82.5% in 
placebo arm). PFS, a primary endpoint, was significantly better in the erlotinib arm than 
the placebo arm (4.8 months vs. 3.7 months; HR 0.72 [95% CI 0.59, 0.88], p=0.0012). 
MST was 15.9 months in the erlotinib arm and 13.9 months in the placebo arm, 
respectively (HR 0.90 [95% CI: 0.74, 1.09], p=0.2686). The difference in OS between 
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Maintenance chemotherapy is a promising strategy in the treatment of NSCLC. 
Recently, pemetrexed and erlotinib have been approved for maintenance chemotherapy 
by both the U.S. Food and Drug Administration and European Medicines Agency; 
however, there has been no conclusive predictor of who will benefit from maintenance 
chemotherapy and which type of maintenance, continuation or switch, is preferred.  
 As for which patients may benefit from maintenance chemotherapy, Sun et al. 
performed an interesting retrospective analysis, according to which, patients with poor 
PS after first-line chemotherapy, large initial tumor, or smaller decrease in tumor size 
after first-line chemotherapy were less likely to receive second-line chemotherapy and 
might derive greater benefit from maintenance chemotherapy.
41
 Considering that recent 
attention to maintenance strategy is based on the advances of second-line chemotherapy 
with more effective and less toxic agents and that only about half of the patients 
received second-line chemotherapy, patients with such characteristics should be offered 
maintenance chemotherapy. 
Regarding the type of maintenance strategy, one possibility is that patients 
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whose response to induction chemotherapy was SD may benefit more from switch 
maintenance than patients who achieve PR or CR. In fact, patients who had SD after 
induction chemotherapy had a more pronounced survival benefit with maintenance 
erlotinib (median 11.9 vs 9.6 months; HR 0.72 [95% CI 0.59, 0.89], p=0.0019) than 
those who had PR or CR (median 12.5 vs 12.0 months; HR 0.94 [95% CI 0.74, 1.20], 
p=0.618) in the SATURN trial.
38
 In contrast, it seems that patients who achieved PR or 
CR may derive more benefit from continuation maintenance than those who have SD 
after induction chemotherapy. Further analysis of past clinical trials of maintenance 
chemotherapy may reveal the influence of the response to induction chemotherapy in 
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Table 1 Randomized trials for treatment duration of platinum-based chemotherapy in NSCLC 
Author Regimen Treatment arms TTP  MST  1-year survival (%)  
Smith14 MVP 3 cycles 5 months 6 months 22 
  6 cycles 5 months 7 months 25 
Socinski15 Carbo/Pac 4 cycles NR 6.6 months 28 
  Until PD NR 8.5 months 34 
von Plessen16 Cis/Vin 3 cycles 16 weeks 28 weeks 25  
  6 cycles 21 weeks 32 weeks 25 
Park17 Cis-based 4 cycles 4.6 months 15.9 months 59 
  6 cycles 6.2 months* 14.9 months 62.4 
NSCLC, non-small-cell lung cancer; MVP, mitomycin + vindesine + cisplatin; Carbo, carboplatin; Pac, paclitaxel;  
Cis, cisplatin; Vin, vinorelbine; TTP, time to progression; NR, not reported; MST, median survival time 
Table 2 Randomized trials for continuation maintenance of cytotoxic agents in NSCLC 
Author Induction 
chemotherapy 
Treatment arms No. of pts PFS  p-value MST  p-value 
Belani18 Carbo/Pac Pac 65 38 weeks NR 75 weeks NR 
  observation 65 29 weeks  60 weeks  
Brodowicz19 Cis/Gem Gem 138 3.6 months* <0.001 10.2 months 0.172 
  observation 68 2.0 months  8.1 months  
Belani20 Carbo/Gem Gem 128 7.4 months NR 8.0 months 0.84 
  observation 127 7.7 months  9.3 months  
Perol21 Cis/Gem Gem 154 3.8 months* <0.0001* NR NR* 
  Erlotinib 155 2.9 months* 0.002** NR NR** 
  observation 155 1.9 months  NR  
NSCLC, non-small-cell lung cancer; Carbo, carboplatin; Pac, paclitaxel; Gem, gemcitabine; PFS, progression-free survival; MST, median survival time;  
NR, not reported; *Gem vs. observation; **Erlotinib vs. observation 
Table 3 Randomized trials for switch maintenance of cytotoxic agents in NSCLC 
Author Induction 
chemotherapy 




p-value MST  
(months) 
p-value 
Westeel22 MIC Vin 91 5.0 0.32 12.3 0.48 
  Observation 90 3.0  12.3  
Fidias23 Carbo/Gem Immediate Doc 153 5.7 0.0001 12.3 0.0853 
  Delayed Doc 156 2.7  9.7  
Ciuleanu24 Platinum-based Pem 441 4.3 <0.0001 13.4 0.012 
  Placebo 222 2.6  10.6  
NSCLC, non-small-cell lung cancer; MIC, mitomycine + ifosfamide + cisplatin; Carbo, carboplatin;  
Gem, gemcitabine; Vin, vinorelbine; Doc, docetaxel; PFS, progression-free survival; MST, median survival time 
Table 4 Randomized trials for continuation maintenance of molecular-targeted agents in NSCLC 
Author Induction 
chemotherapy 




p-value MST  
(months) 
p-value 
Giaccone32 Cis/Gem G250→G250 365 5.3 months 0.7633* 9.8 months 0.4560* 
(INTACT 1)  G500→G500 365 4.6 months  8.7 months  
  Placebo→Placebo 363 5.0 months  9.9 months  
Herbst33 Carbo/Pac G250→G250 345 5.8 months 0.0562* 9.9 months 0.6385* 
(INTACT 2)  G500→G500 347 5.5 months  9.9 months  
  Placebo→Placebo 345 6.0 months  10.9 months  
Herbst36 Carbo/Pac E150→E150 539 5.1 months* 0.36 10.6 months 0.95 
(TRIBUTE)  Placebo→Placebo 540 4.9 months  10.5 months  
Gatzemeier37 Cis/Gem E150→E150 580 23.7 weeks* 0.74 43.0 weeks 0.49 
(TALENT)  Placebo→Placebo 579 24.6 weeks  44.1 weeks  
Sandler26 Carbo/Pac Bev15→Bev15 417 6.2 months* <0.001 12.3 months* 0.003 
(E4599)  Placebo→Placebo 433 4.5 months  10.3 months  
Reck27,28 Cis/Gem Bev15→Bev15 351 6.5 months* 0.03** 13.4 months 0.761** 
(AVAiL)  Bev7.5→Bev7.5 345 6.7 months* 0.003*** 13.6 months 0.420*** 
  Placebo→Placebo 347 6.1 months  13.1 months  
Pirker30 Cis/Vin Ctx→Ctx 557 4.8 months 0.39 11.3 months* 0.044 
(FLEX)  Placebo→Placebo 568 4.8 months  10.1 months  
Lynch31 Carbo/Pac Ctx→Ctx 338 4.40 months 0.2358 9.69 months 0.1685 
(BMS099)  Placebo→Placebo 338 4.24 months  8.38 months  
NSCLC, non-small-cell lung cancer; Cis, cisplatin; Gem, gemcitabine; Carbo, carboplatin; Pac, paclitaxel; Vin, vinorelbine; G, gefitinib; E, erlotinib;  
Bev, bevacizumab; Ctx, cetuximab; PFS, progression-free survival; MST, median survival time; *global ordered log-rank test; **Bev 7.5mg vs. placebo;  
***Bev 15mg vs. placebo 
Table 5 Randomized trials for switch maintenance of molecular-targeted agents in NSCLC 
Author Induction 
chemotherapy 




p-value MST  
(months) 
p-value 
Takeda34 Platinum-based G250 302 4.6 months <0.001 13.7 months 0.11 
(WJTOG 0203)  Observation 301 4.3 months  12.9 months  
Gaafar35 Platinum-based G250 86 4.1 months* 0.0015 10.9 months 0.2 
(EORTC 08021)  Placebo 87 2.9 months  9.4 months  
Cappuzzo38 Platinum-based E150 438 12.3 weeks* <0.0001 12.0 months* 0.0088 
(SATURN)  Placebo 451 11.1 weeks  11.0 months  
Miller, Kabbinavar39,40 Platinum-based/Bev Bev +E150 370 4.76 months* 0.0012 15.9 weeks 0.2686 
(ATLAS)  Bev 373 3.75 months  13.9 weeks  
NSCLC, non-small-cell lung cancer; G, gefitinib; E, erlotinib; Bev, bevacizumab; PFS, progression-free survival; MST, median survival time 
